Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population

Published:2020-11-04 Issue:6 Volume:136 Page:1145-1153
ISSN:0029-7844
Container-title:Obstetrics & Gynecology
language:en
Short-container-title:

Author:

Watson Catherine H.,Fish Laura J.,Falkovic Margaret,Monuszko Karen,Lorenzo Amelia,Havrilesky Laura J.,Secord Angeles Alvarez,Davidson Brittany A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynaecology

Reference28 articles.

1. Phase II trial of alternating courses of megestrol acetate and tamoxifen in endometrial carcinoma: a Gynecologic Oncology Study Group;Fiorica;Gynecol Oncol,2004

2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized placebo-controlled, phase 3 trial;Pujade-Lauraine;Lancet Oncol,2017

3. Niraparib in patients with newly diagnosed advanced ovarian cancer;Gonzalez-Martin;NEJM,2019

4. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;NEJM,2018

5. Patient reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature;Eek;Patient Prefer Adherence,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient reported medication-related problems, adherence and waste of oral anticancer medication over time;European Journal of Hospital Pharmacy;2024-07-17

2. S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis;PLOS ONE;2023-08-11

3. Therapeutic drug monitoring in breast cancer therapy – LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum;Journal of Pharmaceutical and Biomedical Analysis;2023-02

4. Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer;DiSaia and Creasman Clinical Gynecologic Oncology;2023

5. Gestion pratique des inhibiteurs de PARP : Un consensus national DELPHI;Bulletin du Cancer;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3